Baxter(US:BAX) Prnewswire·2025-10-30 12:45Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Allegations - The complaint claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [1]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted and continued to harm patients [1]. - There is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may halt all new sales of these pumps [1]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 15, 2025, with no cost or obligation to participate in the case [2].